Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/27/2025 | $13.00 | Buy | Canaccord Genuity |
Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that it will hold a conference call on Tuesday, August 4, 2026, at 4:30 p.m. ET to discuss its financial results for the second quarter, which ended June 30, 2026. The financial results will be reported in a press release after the close of regular stock market trading hours on Tuesday, August 4, 2026.Investor Conference Call:A live webcast will be held on Tuesday, August 4, 2026, at 4:30 p.m. Eastern Daylight Time (1:30 p.m. Pacific Daylight Time) to discuss Niagen Bioscience’s second quarter financial results and provide a gen
Scientific leader with deep expertise in NAD+ biology, aging research, and global research partnerships to lead the Company's expanding Niagen Research ProgramNiagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the appointment of Abhijit Kale, Ph.D., as Senior Director of Global External Research, effective July 20, 2026.Dr. Kale will lead Niagen Bioscience's Global Niagen Research Program, overseeing the Company's worldwide network of academic and clinical research collaborations while helping shape its scientific research strategy. In this role, he will work closely with leadin
Regulatory recognition in the United States and Europe supports the development of NB4168, a novel small molecule candidate for a rare pediatric disease with no approved treatments Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR
4 - Niagen Bioscience, Inc. (0001386570) (Issuer)
4 - Niagen Bioscience, Inc. (0001386570) (Issuer)
4 - Niagen Bioscience, Inc. (0001386570) (Issuer)
4 - Niagen Bioscience, Inc. (0001386570) (Issuer)
424B5 - Niagen Bioscience, Inc. (0001386570) (Filer)
EFFECT - Niagen Bioscience, Inc. (0001386570) (Filer)
8-K - Niagen Bioscience, Inc. (0001386570) (Filer)
Canaccord Genuity initiated coverage of Niagen Bioscience with a rating of Buy and set a new price target of $13.00
Scientific leader with deep expertise in NAD+ biology, aging research, and global research partnerships to lead the Company's expanding Niagen Research ProgramNiagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the appointment of Abhijit Kale, Ph.D., as Senior Director of Global External Research, effective July 20, 2026.Dr. Kale will lead Niagen Bioscience's Global Niagen Research Program, overseeing the Company's worldwide network of academic and clinical research collaborations while helping shape its scientific research strategy. In this role, he will work closely with leadin
Appointment of renowned gerontologist and mitochondrial biology expert underscores Niagen Bioscience's commitment to advancing cutting-edge NAD+ and healthspan research Niagen Bioscience, Inc. (NASDAQ:NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, is pleased to announce the appointment of Dr. Pinchas Cohen to its Scientific Advisory Board (SAB). Dr. Cohen is an internationally recognized leading expert in healthy aging and mitochondrial biology. He serves as Dean of the University of Southern California (USC) Leonard Davis School of Gerontology and is a Distinguished Professor of Gerontology
Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that it will hold a conference call on Tuesday, August 4, 2026, at 4:30 p.m. ET to discuss its financial results for the second quarter, which ended June 30, 2026. The financial results will be reported in a press release after the close of regular stock market trading hours on Tuesday, August 4, 2026.Investor Conference Call:A live webcast will be held on Tuesday, August 4, 2026, at 4:30 p.m. Eastern Daylight Time (1:30 p.m. Pacific Daylight Time) to discuss Niagen Bioscience’s second quarter financial results and provide a gen
Net sales increased to $31.5 million Gross margin improved to 63.5% Net income of $6.3 million, up $1.3 million from the prior year and adjusted EBITDA of $3.8 million Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the first quarter of 2026. First Quarter 2026 Financial Highlights Total net sales increased 3% to $31.5 million, including $22.4 million from Tru Niagen®. Excluding the recently sold Analytical Reference Standards and Services segment from both periods, net sales rose 5% to $31.1 million. Gross margin of 63.5%, reflecting continued strength in business mix. Net income of $6.3 million, including a $4.8 million gain on the divestiture
Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that it will hold a conference call on Wednesday, May 6, 2026, at 4:30 p.m. ET to discuss its financial results for the first quarter, which ended March 31, 2026. The financial results will be reported in a press release after the close of regular stock market trading hours on Wednesday, May 6, 2026. Investor Conference Call: A live webcast will be held on Wednesday, May 6, 2026, at 4:30 p.m. Eastern Daylight Time (1:30 p.m. Pacific Daylight Time) to discuss Niagen Bioscience's first quarter financial results and provide a